The aluminium fluoride-18 ([ 18 F]AlF) radiolabelling procedure has generated great interest because it is a simple, one-pot method that can be used to directly radiolabel small molecules, peptides and proteins without the requirement for a [ 
Introduction
Positron emission tomography (PET) is an imaging modality used to diagnose and stage diseases by quantitatively monitoring the in vivo distribution of a positron emitting radionuclide bound by chelation or covalent bonding to a biological targeting molecule. Fluorine-18 is often considered the "ideal" PET radioisotope due to a combination of its high positron emission (97%), low positron energy (β + max = 0.64 MeV) ensuring relatively high resolution images and its half-life (109.8 min) which is compatible with multistep synthesis and off-site transport. 1 Generally, the incorporation of fluorine-18 into small organic molecules requires high temperatures and the use of organic solvents; unfortunately these conditions are unsuitable for the labelling of biomolecules such as peptides and small proteins. 2 As a consequence, their radiolabelling can be achieved by a post-radiolabelling attachment of fluorine-18 containing small molecules e.g. N-succinimidyl 4-[ Recently, investigation into the direct radiolabelling of biomolecules with fluorine-18 yielded a one-step procedure comprising the chelation of the aluminium fluoride-18 complex ([ 18 F]AlF) by a macrocyclic ligand (i.e. NOTA, NODA). [4] [5] [6] [7] The rapid [
18 F]AlF technique has generated significant interest owing to the combination of convenient metal based radiochemistry and the excellent decay characteristics of fluorine-18. This approach has been used to successfully radiolabel clickable tags, peptides and small proteins. 5, [8] [9] [10] [11] [12] McBride et al. described the preparation of a lyophilised kit which provided a potential starting point for the standardised production of [ 18 8 The two automated platforms used in the study are widely used for the production of radiopharmaceuticals under GMP conditions. The GE TRACERlab FX FN is built around a fixed reactor vessel with components which are attached to fixed locations.
Reagents are manipulated from glass reservoirs to the reactor by gas pressure. The Trasis AIO platform is a cassette based system that mimics hands on processes (e.g. with the use of replaceable syringes and plastic manifolds) by using syringe drives and tap turners; as the cassette is a disposable component, the synthesis is more GMP compatible than a fixed reactor system. Additionally, the platforms are managed by two different types of automation software. In the GE TRACERlab FX FN system, the process is controlled by a time list with only limited feedback from the platform. The Trasis AIO process is controlled by a combination of timed steps and feedback from the platform regarding that the correct syringe position, temperature or pressure has been achieved.
In this study, the radiolabelling was initially investigated on the GE TRACERlab FX FN system to find indicative trends in radiolabelling performance by changing reaction conditions (e.g. volumes, buffer and substrate quantities) which were subsequently applied to the Trasis AIO platform.
Results and discussion
Selection and preparation of the substrates Two commercially available azamacrocycle-conjugated peptides (NOTA-octreotide and NOTA-RGDfK) and the noncommercially available tetrazine functionalised 1,4,7-triazacyclononane-1,4-diacetic acid (NODA-Tz) were selected for this study to represent the different molecules which have been radiolabelled via the [
18 F]AlF method (Fig. 1 ).
The NODA-Tz small molecule (4) has been designed and synthesised in our lab (Scheme 1). Having previously shown a high [ 18 F]AlF radiolabelling efficiency, the NODA macrocycle was chosen in preference to the more commonly used NOTA chelator. 5, 17 In brief, product 4 was prepared by attaching a 6-carbon alkyl linker to 4-cyanophenol to access compound 1 which was converted into tetrazine 2 in one step following a simple literature procedure. 18 Tetrazine 3, derived from the tosylation of 2, was reacted with NO2AtBu and subsequently deprotected using TFA. The desired product 4 was obtained in a high purity after RP-HPLC purification. All purified compounds were characterised by 1 H and 13 C-NMR and
ESI-HRMS (ESI †).
[ View Article Online is usually achieved using small volumes of a concentrated buffer solution (e.g. 10 μl of 0.5 M NaOAc). 5 The reaction mixture is then incubated at 100-105°C for 15 min and a small excess of the macrocycle-conjugate over Al 3+ is recommended. 14 Typically, the presence of an organic cosolvent (ethanol or acetonitrile) improved the radiolabelling efficiency. 15 Generally, the lowest achievable final reaction volumes (i.e. highest conjugate concentration) and acetate ion concentration afforded increased radiolabelling yields.
14 Both automation systems used in this study are designed for handling large volumes of liquid and therefore the conventional [ 18 F]AlF radiolabelling conditions required modification. To improve the RCY, a glass reactor was used for the radiolabelling of peptides, while a glassy carbon reactor was used for the NODA-Tz. For an efficient transfer to the reaction vessel, the substrate was dissolved in NaOAc buffer (ca. 100 μL, 25 mM, pH 4) and a portion of the organic co-solvent (100 μL). The volume of NaOAc was carefully selected to buffer the [ 18 F]fluoride (300-380 μl aliquot, ca. 1000 MBq, of ca. 2 mL target water) to the optimal pH of 4 while minimising the effect of dilution on the radiolabelling efficiency. A conjugate to AlCl 3 molar ratio of 1 : 0.9 was used.
Acetonitrile was selected as the organic co-solvent for the NODA-Tz substrate due to poor solubility in ethanol. As shown in Fig. 3 and Table S1 , † an increase of the quantities of each of the studied compounds corresponds to an improvement of the [ 18 F]fluoride incorporation, RCY and the SA of the final product. Mostly, the incorporation and radiochemical yields appear to increase with increased amount of conjugate. Effective specific activities of the final products are less affected by the initial substrate quantity. However, full optimisation of the [ 18 F]AlF radiolabelling was beyond the scope of this work and would be largely dependent on the local requirements of the application for the radioconjugate. A single final purification step using HLB-SPE was sufficient to access the final radioconjugates with a RCP >98% (Fig. S2B, S3B , and S4B †). To ensure that the SPE cartridge was efficiently trapping the products and therefore providing the best RCY possible, a test using two cartridges placed in series was carried out. The presence of a negligible amount of radioactivity trapped on the second cartridge confirmed that the products were efficiently loaded by the automated system and were effectively trapped onto the HLB-SPE cartridge. The radioconjugates were eluted with 50% EtOH/H 2 O (300-500 μL) and were suitable for use in pre-clinical applications after dilution with either PBS or 0.9% sodium chloride solution. The total production time was 35 min. A schematic representation of the GE TRACERlab FX FN system is shown in Fig. 2 together with molar ratio) at pH 4 (achieved using NaOAc buffer 25 mM). Acetonitrile was used as organic co-solvent (aqueous solution to organic solvent ratio of 1 : 1.2 v/v) and the reaction mixture was incubated at 105°C for 15 min. A schematic representation of the Trasis AIO system is shown in Fig. 5 together with a list of the radiolabelling reaction steps. A more detailed description of the automated radiolabelling process can be found in the ESI † (Materials and methods, Section 4).
The production time was 26 min. As seen in Fig. 4 , the [ 18 F]fluoride incorporation, the RCY and SA of the radioconjugates were generally higher when the Trasis AIO platform was used compared to the GE 
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TRACERlab FX FN system. The effective control over the movement of reagents and reaction mixtures around the Trasis AIO cartridge based system may be responsible for that. However, the overall production efficiency of the [ 18 F]AlF-NOTARGDfK radioconjugate showed minimal variation between the two platforms. This suggests that the radiolabelling procedure and purification were dependent not only on the reaction conditions but also on the physical and structural properties of the molecules of interest (e.g. amino acid sequence, chain length) which could influence the interaction with the View Article Online surfaces of the reaction vessels and tubing of the automation platform. The general radiolabelling method described here can be used as a starting point for further optimisation to progress a substrate of interest into a clinical setting.
Conclusions
Automated processes are typically required for the production of good manufacturing process (GMP) compliant fluorine-18 radiopharmaceuticals. Examples of PET imaging agents manufactured using this approach include [ 18 where the use of automated platforms has facilitated the progression of these radiotracers into the clinic. [20] [21] [22] [23] [24] Automation of radiopharmaceutical production is desirable to reduce the risk to patients by enabling batch reporting/record keeping, management control and standardisation of processes through the use of standard operating practices (SOPs). Furthermore, production methods are carefully validated to ensure that processes do not introduce pyrogens, microbes or particles into the final patient dose. In addition to reducing the radiochemists contact with the final product, the automation of radiosynthesis and dispensing of the patient dose may reduce the number of batch failures resulting from human error. Automated synthesis modules, particularly cassette based systems, are ideal for use in GMP radiosynthesis as most components are easy to obtain in sterilised packaging and are disposable after a single production run, eliminating the need to further validate a post-production cleaning step. Secondly, these systems are easy to shield which addresses radiation safety concerns associated with handling large amounts of radioactivity. 25 This study aimed to develop a general method suitable for the automation of [ 18 F]AlF radiochemistry which was applied to the GE TRACERlab FX FN and Trasis AIO platforms. The radiolabelling conditions were studied using a selection of azamacrocycle-containing molecules including two commercially available peptides and one in-house synthesised small molecule. Initially, the [ 18 F]AlF radiochemistry was developed using the GE TRACERlab FX FN system and subsequently transferred to the Trasis AIO platform. Purification of the products by HLB-SPE was sufficient to provide radioconjugates with high radiochemical purity (>98%) and the total reaction times were 26-35 min. Currently, the method described is suitable for accessing radioconjugates for pre-clinical studies. Further work would be required to maximise radiochemical yield for a chosen substrate and to optimise the purity profile of the final product prior to patient use. This process should ensure that regulatory parameters are met. The production of large radioactivity batches of GMP grade radiopharmaceuticals for multi-patient doses allows off-site transportation to "satellite" PET centres and facilitates commercial accessibility to these imaging agents. Although the final products were successfully prepared using both automated systems, the cassette based Trasis AIO en- 
